Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OVID
OVID THERAPEUTICS INC.
NASDAQ
$2.71
▼ DOWN 1.81% (-0.05)

KEY STATISTICS

Market Cap$508.59 M
52w High$3.10
52w Low$1.12
Dividend Yield—
Frequency—
P/E-9.34
Volume1.56M
Shares Out.186.64M

COMPANY

LEADERSHIP

Margaret Alexander
CHIEF EXECUTIVE
Margaret Alexander

COMPENSATION 2026

Salary$644,054
Stock Awards$0
Incentive Plan Pay$532,000
All Other Comp.$14,000
Total$1,934,699

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 5, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
23

PRICE TARGET

Target High$7.00
Target Low$4.00
Target Median$5.50
Target Consensus$5.50

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$23.67K
NOV
11
WED

PRICE

$2.71 ▼ DOWN 1.81% (−$0.05)
$2.70$2.75$2.80$2.859:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.71

About Ovid Therapeutics Inc.

https://www.ovidrx.com ↗

Ovid Therapeutics Inc. is a New York-based biopharma developing innovative neurological disorder treatments, including drug candidates like OV101, OV329, OV350, OV882, and OV815, through collaborations with leading organizations.

INDUSTRY

Biotechnology

A PRODUCT OVID THERAPEUTICS INC. IS KNOWN FOR

OV329
OV329

OV329, Ovid Therapeutics' lead GABA-aminotransferase inhibitor, is a potential treatment for treatment-resistant seizures, with plans to enter Phase 2a trials in Q2 2026 for rare neurological disorders involving neuronal hyperexcitability.

COMPETITORS

COMPETITOR
JAZZ COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q4-2025Q2-2026
Reportable Segment$6.27M $132K ▼$718K ▲$733K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
71
LISTED HERE
15
RANKED BY POSITION SIZE
VTI
0.00% · 5.7M
XBI
0.12% · 5.2M
IWM
0.01% · 3.8M
FESM
0.02% · 493.3K
AVSC
0.02% · 236.9K
LABU
0.09% · 190.7K
GSSC
0.05% · 189.8K
XRS2.F
0.01% · 146.9K
PRFZ
0.01% · 94.2K
DFAS
0.00% · 84.0K
RSSL
0.01% · 72.4K
BSVO
0.01% · 51.2K
URTY
0.01% · 6.2K
VIRS
0.02% · 2.3K
RESM
0.01% · 330

INSTITUTIONAL OWNERSHIP

SHARES OWNED
43.42%
HOLDERS
136
TOP 12 OF 136 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
10.7M sh · $17.46M
Janus Henderson Group Plc
10.7M sh · $23.73M
Affinity Asset Advisors, LLC
10.6M sh · $23.61M
Eventide Asset Management, LLC
9.9M sh · $22.02M
Takeda Pharmaceutical Co Ltd
7.5M sh · $9.79M
Adage Capital Partners Gp, L.L.C.
6.2M sh · $13.68M
Balyasny Asset Management L.P.
5.5M sh · $12.28M
Adar1 Capital Management, LLC
4.5M sh · $10.09M
Saturn V Capital Management LLC
4.2M sh · $9.25M
Blackrock Inc.
4.0M sh · $3.07M
Federated Hermes, Inc.
3.6M sh · $7.93M
Point72 Asset Management, L.P.
3.6M sh · $5.79M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Carter Charles Ross
— · —
2026-07-06
★
OFFICER: CHIEF FINANCIAL OFFICER
Carter Charles Ross
— · 206.3K shares
2026-07-06
★
OFFICER: CHIEF FINANCIAL OFFICER
Carter Charles Ross
— · 200.0K shares
2026-07-06
★
OFFICER: CHIEF FINANCIAL OFFICER
Carter Charles Ross
Purchase · 50.0K shares
2026-07-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
BUY 2
4 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM Wedbush OUTPERFORM HC Wainwright & Co. BUY BTIG BUY

SECTORS PEERS

PEERPRICE
STTK$6.88COMPARE
IFRX$2.25COMPARE
WHWK$4.67COMPARE
MGNX$4.18COMPARE
ORMP$5.08COMPARE
CNTB$2.56COMPARE
KLRS$3.98COMPARE
IMA$5.07COMPARE